淡淡向卉
Lv11
50 积分
2023-12-20 加入
-
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1小时前
已完结
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
20天前
已完结
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
2个月前
已完结
-
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
4个月前
已完结
-
Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives
4个月前
已完结
-
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
4个月前
已完结
-
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
5个月前
已完结
-
Exploring the next generation of antibody–drug conjugates
6个月前
已完结
-
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
7个月前
已完结
-
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
7个月前
已完结